Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506363 | 0.84 | PTGES2 (0.48) | CYP1A2CYP3A4CA2CA1ALDH1A1 | |
| SCHEMBL18726029 | 0.78 | CA12 (0.54) | CA12CA9L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL3056484 | 0.75 | CA12 (0.52) | CA12CA9L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL6819636 | 0.75 | CA12 (0.52) | CA12CA9L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL6819477 | 0.75 | CA12 (0.52) | CA12CA9L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL5526515 | 0.75 | LMNA (0.48) | CA12CA9L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL5526511 | 0.75 | LMNA (0.48) | CA12CA9L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL31039996 | 0.74 | CA12 (0.51) | CA12CA9L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL30888830 | 0.74 | CA12 (0.51) | CA12CA9L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL3991308 | 0.72 | CA12 (0.49) | CA12CA9L3MBTL1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729266-B2 | Preparation of N-alkylated opiates by reductive amination | MALLINCKRODT LLC (US) | 2014-05-20 | — | — | US | claimed |
| EP-2683691-B1 | PROCESS FOR THE PREPARATION OF (S)-(+)-10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE AND ESTERS THEREOF BY ENANTIOSELECTIVE REDUCTION OF 10,11-DIHYDRO-10-OXO-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE | JUBILANT LIFE SCIENCES LTD (IN) | 2018-06-06 | — | — | EP | disclosed |
| US-20170190668-A1 | ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE | BIAL - PORTELA & C A S A (PT) | 2017-07-06 | — | — | US | disclosed |
| US-9643929-B2 | Asymmetric catalytic reduction of oxcarbazepine | BIAL—PORTELA & CA, S.A. (PT) | 2017-05-09 | — | — | US | disclosed |
| US-20160176823-A1 | Asymmetric Catalytic Reduction of Oxcarbazepine | BIAL PORTELA & CA SA (PT) | 2016-06-23 | — | — | US | disclosed |
| US-9346760-B2 | Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof | JUBILANT LIFE SCIENCES LIMITED (IN) | 2016-05-24 | — | — | US | disclosed |
| US-9206135-B2 | Asymmetric catalytic reduction of oxcarbazepine | BIAL-PORTELA & CA, S.A. (PT) | 2015-12-08 | — | — | US | disclosed |
| EP-2319836-B1 | Asymmetric catalytic reduction of oxcarbazepine | BIAL PORTELA & CA SA (PT) | 2015-11-25 | — | — | EP | disclosed |
| US-8729266-B2 | Preparation of N-alkylated opiates by reductive amination | MALLINCKRODT LLC (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2683691-A2 | PROCESS FOR THE PREPARATION OF (S)-(+)-OR (R)-(-)-10 HYDROXY DIHYDRODIBENZ[B,F]AZEPINES BY ENANTIOSELECTIVE REDUCTION OF 10, 11-DIHYDRO-10-OXO-5H-DIBENZ[B,F]AZEPINES AND POLYMORPHS THEREOF | Jubilant Life Sciences Limited (IN) | 2014-01-15 | — | — | EP | disclosed |
| EP-2152715-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES | Mallinckrodt Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090203902-A1 | Asymmetric catalytic reduction of oxcarbazepine | BIAL - PORTELA & CA, S.A. (PT) | 2009-08-13 | — | — | US | disclosed |
| US-20090187028-A1 | Process for preparing Chiral Dipeptidyl Peptidase -IV Inhibitor Intermediates | MERCK SHARP & DOHME LLC | 2009-07-23 | — | — | US | disclosed |
| EP-2053032-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE HYDROXYCARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Kaneka Corporation (JP) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009037416-A1 | PROCESS FOR PREPARING SULPHONAMIDES | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037497-A1 | PROCESS FOR PREPARING SULPHONAMIDES | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008137672-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES | MALLINCKRODT INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1915346-A1 | ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE | Portela & C.A. S.A (PT) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007012793-A1 | ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE | PORTELA & C.A., S.A. (PT) | 2007-02-01 | — | — | WO | disclosed |
| WO-2005028437-A1 | PROCESS FOR THE PREPARATION OF SECONDARY AMINOALCOHOLS | AVECIA PHARMACEUTICALS LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203902-A1 | Asymmetric catalytic reduction of oxcarbazepine | HRH4, HRH3, HRH2 | CA12 397/4885CA9 177/4885L3MBTL1 3324/4885 |
| US-20160176823-A1 | Asymmetric Catalytic Reduction of Oxcarbazepine | HRH4, HRH3, HRH2 | CA12 397/4885CA9 177/4885L3MBTL1 3324/4885 |
| US-20170190668-A1 | ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE | HRH4, HRH3, HRH2 | CA12 397/4885CA9 177/4885L3MBTL1 3324/4885 |
| US-20090187028-A1 | Process for preparing Chiral Dipeptidyl Peptidase -IV Inhibitor Intermediates | DPP4, DPP3, DPP7 | CA12 3061/4885CA9 678/4885L3MBTL1 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.